amgen glp 1 drug π The next trillion-dollar war has begun Drugmakers including Eli Lilly, Novo Nordisk, Pfizer, Amgen, AstraZeneca and others are racing beyond today's GLP-1 drugs. New pills, monthly injections and next-generation obesity Patent and Innovation Trends in
Description
The clinical success of dual and triple incretin agonists has validated the concept that engaging multiple complementary pathways within a single molecular framework can yield superior efficacy without proportionally increasing toxicity (Finan et al., 2016)
After screening by title and abstract, 16 articles were available to be assessed in full-text screening
Craddock N, ODonovan MC, Owen MJ
Do GLP-1 analogs have a place in the treatment of PCOS
doi: 10.1345/aph.1H060 20 SeoYG
They require monitoring from a licensed medical professional
